Odonate Therapeutics, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018017889 Filed on July 30, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.4M
YoY Change
Cash & Equivalents $177.7M $8.434M
Short-Term Investments
Other Short-Term Assets $3.327M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $180.8M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.504M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $748.0K
YoY Change
Total Long-Term Assets $2.252M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $180.8M
Total Long-Term Assets $2.252M
Total Assets $183.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.702M
YoY Change
Accrued Expenses $5.553M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.29M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $390.0K
YoY Change
Total Long-Term Liabilities $390.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.29M
Total Long-Term Liabilities $390.0K
Total Liabilities $10.68M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$75.56M
YoY Change
Common Stock $247.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $172.3M
YoY Change
Total Liabilities & Shareholders Equity $183.0M
YoY Change

Cashflow Statement

Concept 2018 Q2 2017 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Operating Expenses
OperatingExpenses
6626000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3900000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36660000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5736000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
890000
us-gaap Net Income Loss
NetIncomeLoss
-6626000
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
39000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7512000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
390000
CY2018Q2 us-gaap Liabilities
Liabilities
10684000
CY2017Q4 us-gaap Liabilities
Liabilities
7512000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
244000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
240000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
247641000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235034000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-75563000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39292000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
172322000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
195982000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183006000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203494000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26890708
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26890356
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26890708
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26890356
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17024000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3282000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31484000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2755000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
618000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5176000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
19779000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
3900000
us-gaap Operating Expenses
OperatingExpenses
36660000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19779000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
389000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3900000
us-gaap Net Income Loss
NetIncomeLoss
-36271000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.49
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24402466
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12740822
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24376885
us-gaap Share Based Compensation
ShareBasedCompensation
2600000
us-gaap Share Based Compensation
ShareBasedCompensation
310000
odt Non Cash Contributions For Expenses
NonCashContributionsForExpenses
64000
odt Non Cash Contributions For Expenses
NonCashContributionsForExpenses
1688000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6626000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
389000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-19390000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11609062
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1399000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
51000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2343000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
437000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
433000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29085000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4112000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1289000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1289000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9848000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9986000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
98000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9946000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9983000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20428000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5835000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198105000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2599000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177677000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8434000
odt Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
51000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
113000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ODONATE THERAPEUTICS, INC.</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Notes to Condensed Financial Statements</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.08%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Odonate Therapeutics, Inc. (&#8220;Odonate&#8221; or the &#8220;Company&#8221;) is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company&#8217;s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: significant activity against chemotherapy-resistant tumors; oral administration with a low pill burden; a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; and no history of hypersensitivity (allergic) reactions. In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two, multicenter, Phase 2 studies. The Company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA. The Company&#8217;s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.08%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2017, the Company closed its initial public offering (&#8220;IPO&#8221;) of 6,250,000 shares of common stock at a public offering price of $24.00 per share. On January 10, 2018, the Company sold 441,073 additional shares of common stock pursuant to an option granted to the underwriters in the Company&#8217;s IPO. The aggregate gross proceeds from the IPO were $160.6 million, and the net proceeds were $147.3 million after deducting underwriting discounts and commissions and offering costs.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:3.08%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2018, the Company had $177.4 million in cash. The Company has incurred operating losses and negative cash flows from operations since inception. Management believes the Company&#8217;s existing cash as of June&#160;30, 2018 will be sufficient to meet the Company&#8217;s anticipated cash requirements through at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;).</p></div>
odt Cash Requirements Minimum Period
CashRequirementsMinimumPeriod
P1Y
CY2018Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q2 odt Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
3344000
CY2017Q4 odt Accrued Clinical Development Costs Current
AccruedClinicalDevelopmentCostsCurrent
3033000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2115000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
169000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
94000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3115101
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1087173
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
558657
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3643617
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
813667
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.25
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.32
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.023
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.021
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.026
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.023
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1589000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
301000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
310000
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0001564590-18-017889-index-headers.html Edgar Link pending
0001564590-18-017889-index.html Edgar Link pending
0001564590-18-017889.txt Edgar Link pending
0001564590-18-017889-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
odt-10q_20180630.htm Edgar Link pending
odt-20180630.xml Edgar Link completed
odt-20180630.xsd Edgar Link pending
odt-20180630_cal.xml Edgar Link unprocessable
odt-20180630_def.xml Edgar Link unprocessable
odt-20180630_lab.xml Edgar Link unprocessable
odt-20180630_pre.xml Edgar Link unprocessable
odt-ex311_6.htm Edgar Link pending
odt-ex312_8.htm Edgar Link pending
odt-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending